10rx vs MEDVi
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, 10rx opens cheaper — $99.67/mo against $249, and 10rx finishes ahead, 8.1 to 7.2. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
10rx
Compounded; GLP-1 options as low as under $100/mo
Compounded GLP-1 + GIP
MEDVi
$299 is the locked-in refill price; $179 first-month 'SUMMER Sale' on the main and affiliate-landing funnels; a $149 first-month variant runs on the ?page=multi3 funnel. Affiliate landing (?page=multi) shows $179.
Flat 'Starting at $249' — no intro discount shown.
$99 Membership + Medication Cost — medication cost not published (varies/insurance may reimburse). 'Availability is subject to change.'
$99 Membership + Medication Cost — medication cost not published. COMPOUNDED tirzepatide ($349 in our current entry) is no longer published anywhere on glp1.medvi.org, home.medvi.org, or the intake flow (0 mentions) — treat as discontinued/not published, do not carry the $349 row forward.
What’s included
10rx
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
MEDVi
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
In the price
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
10rx
8.1/10
MEDVi
7.2/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | 10rx | MEDVi |
|---|---|---|
| Starting Price | ✓$99.67/mo | $249/mo |
| Features | ✓8 features | 7 features |
| States Available | Not disclosed | 48 |
| Compounded | — | ✓ Yes |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | ✓None | 1 warning |
About 10rx
10rx sets flat monthly rates on compounded GLP-1: semaglutide at $99.67, tirzepatide at $149.67, with NAD+ and sermorelin sold separately for energy and recovery. A free health quiz online reaches a board-certified telehealth doctor, who reads your history before writing anything, and licensed pharmacy partners handle discreet delivery. The company states it reaches every one of the 50 states. What it does not state is its operating company, its pharmacies, or any terms page.
Read our full 10rx review →About MEDVi
Two clinical groups do the treating at MEDVi: CareGLP Affiliated P.C.s, plus clinicians from OpenLoop Health. Its weight-loss menu holds compounded GLP-1s, injections and tablets alike, the molecule being semaglutide, next to Zepbound and Wegovy under their brand names. Licensed US pharmacies fill all of it.
Read our full MEDVi review →Pros & Cons
10rx
What we like
- Semaglutide at $99.67 a month, 47% below the $189 median for the same drug and form across this register
- Tirzepatide at $149.67 a month, 44% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
MEDVi
What we like
- Semaglutide at $249 a month, within the normal band around this register's $189 median for the same drug and form
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping, coaching
- Coverage is published for 48 states
- Names 3 dispensing pharmacies, which most sellers in this register do not do
Watch-outs
- 1 FDA warning letter matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
10rx takes it, 8.1 against 7.2, and it is especially strong on semaglutide at $99.67/month, 47% under the register median. MEDVi is no weak second and may fit you better on knowing which pharmacy fills the vial — it names Triad Rx.
Choose 10rx if…
You want semaglutide at $99.67/month, 47% under the register median and an opening price near $99.67 a month.
Choose MEDVi if…
You want knowing which pharmacy fills the vial — it names Triad Rx and an opening price near $249 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Strut Health
Semaglutide at $99/month, 48% under the register median
From $99/mo
Get started →Oak
Semaglutide at $119/month, 37% under the register median
From $119/mo
Get started →Found
Tirzepatide at $169/month, 37% under the register median
From $99/mo
Get started →10rx vs MEDVi: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring 10rx and MEDVi head-to-heads in the same category.
- 10rx vs Trimi Health
- 10rx vs Embody
- 10rx vs He & She MD
- MEDVi vs Lean Meds
- MEDVi vs NextMeds
- MEDVi vs bmiMD
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.